Plain-English translation of NCT07697859 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing the best way to combine PD-1 inhibitors—a type of immunotherapy that helps your immune system fight cancer—with radiation therapy for esophageal squamous cell carcinoma (a type of esophageal cancer) that has spread to only a few distant sites. The study wants to find out whether starting radiation therapy early or waiting until later in your immunotherapy treatment works better and is safer for you.
Even with the best current treatments, survival rates for esophageal cancer remain low, and doctors are not sure about the best order and timing for combining immunotherapy with radiation therapy. This trial aims to answer that important question so future patients get the most effective and tolerable treatment plan.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups: one group will start radiation therapy before completing their first two immunotherapy cycles, while the other group will wait and start radiation therapy after completing four immunotherapy cycles. You will receive the immunotherapy medication on a standard schedule and will have regular visits to monitor your health, blood work, and imaging scans to see how well the treatment is working.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China